FUCIDIN OINTMENT 2%
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
12-07-2017
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
FUSIDATE SODIUM
Fáanlegur frá:
LEO PHARMA INC
ATC númer:
D06AX01
INN (Alþjóðlegt nafn):
FUSIDIC ACID
Skammtar:
2%
Lyfjaform:
OINTMENT
Samsetning:
FUSIDATE SODIUM 2%
Stjórnsýsluleið:
TOPICAL
Einingar í pakka:
5G/30G
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANTIBIOTICS
Vörulýsing:
Active ingredient group (AIG) number: 0114229001; AHFS:
Leyfisstaða:
MARKETED
Leyfisdagur:
1984-12-31
Vara einkenni
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
FUCIDIN
®
Fusidic acid
2% Cream
Sodium fusidate
2% Ointment
Antibiotic
LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.com/canada
Date of initial
approval:
Aug 9, 1985
Date of Revision:
July 10, 2017
Submission Control No.: 202631
®Registered trademark of LEO Pharma A/S used under license by LEO
Pharma Inc., Thornhill, ON
LEO®
_ _
_FUCIDIN® (fusidic acid/sodium fusidate) Product Monograph, version
1.04_
_ _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
1
INDICATIONS
........................................................................................................................
3
2
CONTRAINDICATIONS
........................................................................................................
3
3
DOSAGE AND ADMINISTRATION
......................................................................................
3
3.1
Administration
.............................................................................................................
3
4
OVERDOSAGE
.....................................................................................................................
4
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
.............................. 4
6
WARNINGS AND PRECAUTIONS
.......................................................................................
5
6.1
Special Populations
....................................................................................................
5
6.1.1
Pregnant Women
....................................................................................................
5
6.1.2
Breast-feeding
.........................................................................................................
6
7
ADVERSE REACTIONS
.......................................................................................................
6
7.1
Adverse Reaction Overview
....................................
Lestu allt skjalið
